Abivax SA (ABVX) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Abivax SA (ABVX) over the past year, gaining 434.2% versus a gain of 0.0%. Abivax SA is the larger company by market cap ($7.51 billion vs $7.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | PRAX |
|---|---|---|
| Share price | $86.09 | $263.80 |
| Market cap | $7.51B | $7.37B |
| 1-day change | -1.06% | -5.12% |
| YTD return | -35.48% | -5.67% |
| 1-year return | 0.00% | +434.24% |
| 5-year return | — | -7.37% |
| EPS (TTM) | $-6.08 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | — | $-303.27M |
| 52-week high | $148.83 | $392.70 |
| 52-week low | $69.81 | $50.56 |
| Distance from 52-week high | -42.16% | -32.83% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.51% | +144.29% |
| Average volume | 1.10M | 403.18K |
| Shares outstanding | 87.27M | 27.92M |
| Employees | 98 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed ABVX by 434.2 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
ABVX vs PRAX FAQ
Which is bigger, Abivax SA or Praxis Precision Medicines?
Abivax SA (ABVX) is larger, with a market capitalization of $7.51B compared with $7.37B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, ABVX or PRAX?
PRAX returned +434.24% over the past 12 months, compared with 0.00% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.